Showing results (11-20 of 74) with videos related to
Sort By:
Pageof 8
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 26, 2015
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosisDonald R VanDevanter, Nathan J Morris, Michael W KonstanRespiratory Medicine|January 3, 2012
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?David Lo, Donald R VanDevanter, Patrick Flume, et al.Annals of the American Thoracic Society|August 13, 2016
Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed TherapiesDonald R VanDevanter, Sonya L Heltshe, John J LiPumaJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 23, 2009
Characterizing aggressiveness and predicting future progression of CF lung diseaseMichael W Konstan, Jeffrey S Wagener, Donald R VanDevanterThe Journal of Pediatrics|August 20, 2014
Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012Donald R VanDevanter, David J Pasta, Michael W KonstanJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 11, 2015
Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosisDonald R VanDevanter, David J Pasta, Michael W KonstanJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 21, 2023
Re-examining baseline lung function recovery following IV-treated pulmonary exacerbationsSonya L Heltshe, Renee Russell, Donald R VanDevanter, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 8, 2020
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosisDonald R VanDevanter, Sonya L Heltshe, Jay B Hilliard, et al.Respiratory Research|October 8, 2010
Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbationsDonald R VanDevanter, Mary A O'Riordan, Jeffrey L Blumer, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 20, 2020
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trialsDonald R VanDevanter, Nicole Mayer Hamblett, Noah Simon, et al.Pageof 8